PFE - Pfizer Inc.
36.46 0.00 (0.00%)
After hours: 4:32PM EDT
| Previous close | 36.22 |
| Open | 36.29 |
| Bid | 36.38 x 46000 |
| Ask | 36.51 x 41800 |
| Day's range | 36.21 - 36.58 |
| 52-week range | 32.32 - 39.43 |
| Volume | 20,247,735 |
| Avg. volume | 21,231,350 |
| Market cap | 213.275B |
| Beta | 0.93 |
| PE ratio (TTM) | 10.13 |
| EPS (TTM) | 3.60 |
| Earnings date | 31 Jul 2018 |
| Forward dividend & yield | 1.36 (3.74%) |
| Ex-dividend date | 2018-05-10 |
| 1y target est | 39.86 |
- Simply Wall St.•26 minutes ago
Should You Buy Pfizer Inc (NYSE:PFE) At This PE Ratio?
Pfizer Inc (NYSE:PFE) is trading with a trailing P/E of 9.9x, which is lower than the industry average of 24x. Although some investors may jump to the conclusion that thisRead More...
- Zacks•7 hours ago
Amgen Gets EU Nod to Add Survival Data on Blincyto's Label
Amgen (AMGN) gets approval from the European Commission to add overall survival (OS) data from the TOWER study on the label of its leukemia drug, Blincyto.
- Market Realist•7 hours ago
A Look at Allergan’s Valuation as of June 19
Allergan (AGN), a leading specialty pharmaceutical company, is focused on developing, manufacturing, and commercializing pharmaceutical and biologic products.
- Forbes•9 hours ago
There Go Those Drug Companies Inventing New Diseases Again
Another quote used by Walsh, this one from Cindy Pearson of the National Women’s Health Network, claims that “Osteopenia is disease-mongering plain and simple.” Osteopenia is a term used to describe bone-thinning and is considered to be the mid-point between healthy bone and osteoporosis. Is osteopenia (bone-thinning) a disease?
- Zacks•9 hours ago
Sarepta's Stock Soars on Encouraging Gene Therapy Results
Sarepta (SRPT) shares skyrocket on better-than-expected results from an early-stage study, evaluating its gene therapy as a treatment for DMD patients.
- Motley Fool•11 hours ago
Forget Johnson & Johnson: Here Are 2 Better Dividend Stocks
J&J's dividend is good. But these are even better.
- Zacks•yesterday
Myriad Genetics Wins FDA SPMA Nod for BRACAnalysis CDx
The FDA accepts Myriad Genetics' (MYGN) supplementary premarket approval (sPMA) application for BRACAnalysis CDx to identify the best responders to Pfizer's PARP inhibitor, talazoparib.
- CNBC•yesterday
There's one Dow stock having a great day — Verizon
Verizon was the only DJIA member trading significantly in the green on Tuesday. Deutsche Bank upgraded the wireless maker, saying shares were cheap.
- Forbes•yesterday
A Gene Therapy Appears To Replace Missing Protein In Muscular Dystrophy Patients
An experimental gene therapy appeared to dramatically increase the production of a muscle-making protein in three young boys with Duchenne muscular dystrophy, a deadly and irreversible disease, according to results being presented by the drugmaker Sarepta Therapeutics at an investor event this morning. “We think this has huge implications for the treatment of this disease,” says Jerry R. Mendell, the principal investigator in the Center for Gene Therapy at the Research Institute of Nationwide Children’s Hospital, who is leading the study for Sarepta. “Being in this field doing clinical research for many years, I learned to be cautious,” says Ron Crystal, chairman of genetic medicine at Weill Cornell Medicine.
- Business Wire•yesterday
Pfizer Invites Public To View And Listen To Webcast Of July 31 Conference Call With Analysts
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, July 31, 2018. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2018 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors.
- Market Realist•yesterday
Myriad Stock Rose on FDA Supplementary Premarket Approval
On June 18, Myriad Genetics (MYGN) announced that the FDA accepted its supplementary premarket approval (or sPMA) application for BRACAnalysis CDx, a companion diagnostic with Pfizer’s (PFE) talazoparib, a PARP (poly ADP ribose polymerase) inhibitor. Pfizer has already filed a new drug application (or NDA) for the approval of talazoparib. The FDA has granted Pfizer’s NDA for talazoparib “priority review” status and provided a Prescription Drug User Fee Act action date of December 2018.
- Motley Fool•3 days ago
Better Buy: Pfizer Inc. vs. Johnson & Johnson
How do these two big pharma stocks compare in a head-to-head match?
- CNBC•4 days ago
5 biggest risks of sharing your DNA with consumer genetic-testing companies
Consumer DNA genetic testing kits are a booming business, and the biggest risk isn't necessarily uncovering a health scare; it's what these companies may do, or be forced to do, with your genetic data.
- Motley Fool•5 days ago
Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers
These two small biotechs with promising NASH drugs could attract several big suitors.
- MarketWatch•6 days ago
ViiV Healthcare reports positive results for late-stage HIV trials
ViiV Healthcare, which is majority-owned by GlaxoSmithKline and has Pfizer Inc. and Shionogi as shareholders, reported on Thursday positive early results from two late-stage trials testing its two-drug regimen in patients new to HIV treatment relative to a three-drug regimen. GlaxoSmithKline shares rose 2.4% in premarket trade on Thursday after the news. It plans to file for regulatory approvals of the two-drug regimen, composed of the drugs dolutegravir and lamivudine, later this year, and also has plans to present full results at an upcoming scientific meeting.
- Zacks•7 days ago
Merck's (MRK) Keytruda Gets FDA Approval for Cervical Cancer
Merck's (MRK) Keytruda receives accelerated approval for the treatment of patients with advanced cervical cancer.
- Forbes•7 days ago
This Rare 10.5% Dividend Won't Be Cheap For Long
Let’s be honest: with an income stream like that, backed by household names like Pfizer and AT&T—more on these two stocks below—you’d leap at the chance, right? Funny thing is, for a brief, shining moment in the not-so-distant past (early March 2009), many blue chips actually did deliver payouts of 7%, 10% and more. You needed nerves of steel to plunge in while everyone else was sprinting from the worst market crash since 1929.
- Simply Wall St.•8 days ago
Should You Buy Pfizer Inc (NYSE:PFE) For Its Dividend?
Dividends play a key role in compounding returns over time and can form a large part of our portfolio return. Pfizer Inc (NYSE:PFE) has returned to shareholders over the pastRead More...
- Motley Fool•8 days ago
Can This Pharma's $14 Billion Bet Succeed?
A big component of Pfizer's Medivation purchase could get a chance to prove itself soon.
- Business Wire•8 days ago
Pfizer Announces Extension of Zithromax® Antibiotic Donation Program through 2025 to Help Eliminate World’s Leading Infectious Cause of Blindness
Pfizer Inc. announced today it will extend its donation of the antibiotic Zithromax® (azithromycin) to the International Trachoma Initiative through 2025, building on the company’s 20-years of work to help eliminate the world’s leading infectious cause of blindness. Approximately 163 million people are at risk of developing the disease and this recommitment ensures that Pfizer, through the International Trachoma Initiative (ITI), will continue to provide trachoma endemic countries with donated antibiotics that are a critical component of the global strategy to eliminate this neglected tropical disease (NTD). Pfizer’s continued donation program will help accelerate significant progress made in the last decade to reduce trachoma through increased donations, resulting in a roughly 50 percent decrease in the number of people at risk of trachoma worldwide today compared to 2011.
- Motley Fool•8 days ago
3 Stocks to Supplement Your Social Security Income
These stocks have what it takes to help meet your financial needs in retirement beyond what Social Security can provide.
- Zacks•9 days ago
The Zacks Analyst Blog Highlights: Pfizer, Union Pacific, Broadcom, KeyCorp and Ulta Beauty
The Zacks Analyst Blog Highlights: Pfizer, Union Pacific, Broadcom, KeyCorp and Ulta Beauty
- Forbes•9 days ago
A Story Of Devastation And Rebirth: The Former Pfizer Research Labs In Ann Arbor
December 4, 2006 proved to be a fateful day for Pfizer–the day when it announced that the highly touted cholesterol modifying drug, torcetrapib, was being dropped from development. This drug had potent cholesterol modifying properties: doubling a heart patient’s HDL-c while simultaneously lowering LDL-c by 20% (on top of Lipitor’s 40% LDL-c lowering effect). When patients took torcetrapib in combination with Lipitor, their lipoprotein levels essentially normalized, results that were unprecedented.
- Motley Fool•12 days ago
3 Dividend Stocks Ideal for Retirees
Whether it's a steady source of income, capital appreciation to grow your nest egg, or both, these three dividend stocks look like smart choices.
- Market Realist•12 days ago
The FDA and EMA on Pfizer’s Talazoparib
On June 7, Pfizer (PFE) announced that the FDA and the European Medicines Agency (or EMA) provided updates on the regulatory submissions of Talazoparib for the treatment of locally advanced or metastatic breast cancer. In this article, we’ll examine the drug, regulatory submissions, and clinical trials related to the drug.
